Endometrial cancer diagnoses in times of the covid-19 pandemic
DOI:
https://doi.org/10.47456/rbps.v26isupl_1.44391Keywords:
Endometrial Neoplasms, Endometrial Ablation Techniques, COVID-19Abstract
Introduction: Endometrial cancer (EC) is the sixth most frequent among women. During the COVID-19 pandemic, there was a severe compromise of the health system, contributing to later diagnoses of EC and directly interfering with the prognosis. Objectives: To evaluate the prevalence of EC in pandemic years among patients at the Gynecology Department of the University Hospital. Methods: Patients with histological diagnosis of EC from January 2020 to December 2022. Patients with abnormal uterine bleeding (AUB) and endometrial thickness (EE) greater than or equal to 12mm underwent Novak Curettage (NC); unsuccessful patients with NC or EE greater than 12mm or inconclusive results on NC underwent hysteroscopy. Results: 25 patients were diagnosed with EC. Among them, 22 (88%) had SUA as their main symptom and 20 (80%) were post-menopausal. CN was diagnosed in 12 patients (48%), and 8 (32%) were diagnosed by hysteroscopy. Ten patients had the diagnosis by incidental finding. The mean age, BMI, and EE were 59.6 years, 30.5, and 20.9 mm, respectively. The mean waiting time from first symptom and treatment was 12.4 months, the mean time to diagnosis with CN was eight months, and with hysteroscopy was 16.5 months. The most prevalent histological subtype was endometrioid adenocarcinoma (32%). Conclusion: SUA is a symptom that should be investigated. The pandemic context has hampered the diagnosis and treatment of EC cases. Optimizing the avenues of suspicion, diagnosis, and treatment of endometrial cancer as early as possible is crucial, aiming at its more significant therapeutic and possibly curative success.
Downloads
References
Ferlay J, et al. Cancer Statistics for the Year 2020: an Overview. Int J Cancer. 2021 Apr 5;149(4).
Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Esti¬mates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 Feb 4;71(3):209-49.
Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer; 2020. Available from: http://publications.iarc.fr/586.
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Atlas da mortalidade. Rio de Janeiro: INCA; 2020. Available from: https://www.inca.gov.br/app/mortalidade.
Ribeiro CM, Correa FM, Migowski A. Efeitos de curto prazo da pandemia de COVID-19 na realização de procedimentos de rastreamento, investigação diagnóstica e tratamento do câncer no Brasil: estudo descritivo, 2019-2020. Epidemiol Serv Saúde. 2022;31(1):e2021405.
Clarke MA, et al. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women. JAMA Intern Med. 2018 Sep 1;178(9):1210.
Furness S, et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD000402.
Mourits M. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol. 2001 May;97(5):855-66.
Amant F, et al. Endometrial cancer. Lancet. 2005 Aug 1;366(9484):491-505.
Cao Z, et al. Association of obesity status and metabolic syn¬drome with site-specific cancers: a population-based cohort study. Br J Cancer. 2020 Oct 1;123(8):1336-44.
Karageorgi S, et al. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses’ Health Study cohort 1976-2004. Int J Cancer. 2009 Jun 23;126(1):208-16.
Gupta S, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019. J Natl Compr Canc Netw. 2019 Sep;17(9):1032-41.
Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individ¬ual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015 Sep;16(9):1061-70.
Iversen L, et al. Lifetime cancer risk and combined oral contra¬ceptives: the Royal College of General Practitioners’ Oral Con¬traception Study. Am J Obstet Gynecol. 2017 Jun 1;216(6):580. e1-580.e9.
Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer. 2003 Mar 11;104(6):669-76.
Wilczyński M, Danielska J, Wilczyński J. An update of the clas¬sical Bokhman’s dualistic model of endometrial cancer. Meno¬pausal Rev. 2016;(2):63-8.
Rodríguez Cerezo CR, Estrada Soria L, Toro Calzada RJ. [Histo¬pathological correlation of biopsy of the endometrium between Novak’s catheter and curettage]. Ginecol Obstet Mex. 2000 Sep;68:394-9.
Clark TJ, et al. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. BJOG. 2002 Mar;109(3):313-21.
Su D, et al. Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmeno¬pausal women: a systematic review and meta-analysis. Ann Pal¬liat Med. 2021 Oct;10(10):10840-48.
Colombo N, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016 Jan 1;27(1):16-41.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Brazilian Journal of Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors and reviewers must disclose any financial, professional, or personal conflicts of interest that could influence the results or interpretations of the work. This information will be treated confidentially and disclosed only as necessary to ensure transparency and impartiality in the publication process.
Copyright
RBPS adheres to the CC-BY-NC 4.0 license, meaning authors retain copyright of their work submitted to the journal.
- Originality Declaration: Authors must declare that their submission is original, has not been previously published, and is not under review elsewhere.
- Publication Rights: Upon submission, authors grant RBPS the exclusive right of first publication, subject to peer review.
- Additional Agreements: Authors may enter into non-exclusive agreements for the distribution of the RBPS-published version (e.g., in institutional repositories or as book chapters), provided the original authorship and publication by RBPS are acknowledged.
Authors are encouraged to share their work online (e.g., institutional repositories or personal websites) after initial publication in RBPS, with appropriate citation of authorship and original publication.
Under the CC-BY-NC 4.0 license, readers have the rights to:
- Share: Copy and redistribute the material in any medium or format.
- Adapt: Remix, transform, and build upon the material.
These rights cannot be revoked, provided the following terms are met:
- Attribution: Proper credit must be given, a link to the license provided, and any changes clearly indicated.
- Non-Commercial: The material cannot be used for commercial purposes.
- No Additional Restrictions: No legal or technological measures may be applied to restrict others from doing anything the license permits.
